IntelGenx Technologies (OTCMKTS:IGXT) Stock Crosses Below Fifty Day Moving Average of $0.52

Share on StockTwits

Shares of IntelGenx Technologies Corp. (OTCMKTS:IGXT) passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $0.52 and traded as low as $0.50. IntelGenx Technologies shares last traded at $0.50, with a volume of 4,606 shares changing hands.

Several equities research analysts recently issued reports on IGXT shares. ValuEngine lowered IntelGenx Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, February 19th. HC Wainwright reissued a “buy” rating and set a $2.00 price target on shares of IntelGenx Technologies in a research report on Tuesday, March 26th.

The company has a quick ratio of 3.93, a current ratio of 4.08 and a debt-to-equity ratio of 1.02. The stock has a market cap of $47.42 million, a PE ratio of -3.62 and a beta of 2.00.

IntelGenx Technologies (OTCMKTS:IGXT) last issued its quarterly earnings data on Friday, March 22nd. The company reported ($0.03) EPS for the quarter. The company had revenue of $0.65 million for the quarter, compared to the consensus estimate of $0.20 million. IntelGenx Technologies had a negative return on equity of 209.70% and a negative net margin of 521.60%. Research analysts anticipate that IntelGenx Technologies Corp. will post -0.07 EPS for the current year.

WARNING: This piece was first published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4380234/intelgenx-technologies-otcmktsigxt-stock-crosses-below-fifty-day-moving-average-of-0-52.html.

IntelGenx Technologies Company Profile (OTCMKTS:IGXT)

IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease.

See Also: Discover Your Risk Tolerance

Receive News & Ratings for IntelGenx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Sensient Technologies  to Release Earnings on Friday
Sensient Technologies to Release Earnings on Friday
Zacks Investment Research Downgrades Aurora Cannabis  to Sell
Zacks Investment Research Downgrades Aurora Cannabis to Sell
Abbott Laboratories  Given New $93.00 Price Target at Morgan Stanley
Abbott Laboratories Given New $93.00 Price Target at Morgan Stanley
ValuEngine Downgrades AMBEV S A/S  to Hold
ValuEngine Downgrades AMBEV S A/S to Hold
Aaron’s  Price Target Raised to $70.00
Aaron’s Price Target Raised to $70.00
Alcoa  Stock Rating Upgraded by ValuEngine
Alcoa Stock Rating Upgraded by ValuEngine


© 2006-2019 Ticker Report